Weight loss

Weight Loss

Losing Weight When You Already Have Type 2 Diabetes

Dr. Himalay Agarwal

Dr. Himalay Agarwal

Consultant Internal Medicine

You have probably been told that diabetes makes weight loss harder. The evidence is more mixed than that. When researchers put people with and without diabetes through the same programme, two studies found similar losses, and some earlier studies found that people with diabetes lost less.

What changes a great deal is which medicines you take. Some glucose-lowering medicines push weight up, others push it down, and the same calorie deficit (eating fewer calories than you burn) behaves differently depending on which you take. This article sets out what the evidence shows, where the safety limits are, and what belongs in a conversation with your prescriber.

Key Takeaways

  • Mixed evidence: Studies disagree on whether diabetes makes weight loss harder, so no average "diabetes penalty" is established.
  • Your medicines matter: Insulin, sulfonylureas, meglitinides and thiazolidinediones usually add weight, while SGLT2 inhibitors and GLP-1 receptor agonists usually reduce it.
  • Remission is possible in selected groups: In the DiRECT and DIADEM-I trials, intensive supervised programmes led to remission in 46% and 61% of participants at one year, and in 86% of DiRECT participants who lost at least 15 kg.
  • Remission is not a cure: It needs HbA1c checks at least yearly and continued eye, kidney and foot surveillance.
  • Safety shapes the plan: Hypoglycaemia risk, retinopathy, kidney disease and neuropathy all change how a calorie deficit should be attempted.
  • Review before you start: Take your medicine list, HbA1c and complication records to your prescriber first, and never stop or change a medicine on your own.

Is Weight Loss Actually Harder With Diabetes?

Comparing a diabetes trial with an unrelated trial in people without diabetes tells you nothing, because the people and the programmes differ. The useful comparisons put both groups through the same programme. Two did:

  • 1995 behavioural programme: Guare, Wing and Grant treated 43 women together, 20 with type 2 diabetes and 23 without, matched for age and weight. After 16 weeks the women lost 7.4 kg and 6.4 kg respectively, which the authors described as comparable. Over the next year, the women with diabetes regained 5.4 kg and the others regained 1.0 kg (p = 0.058). That points towards poorer maintenance but does not meet the usual threshold for statistical significance.
  • 2022 Finnish digital coaching cohort: This study followed 1,189 adults in a 12-month online programme, and 193 of them reported type 2 diabetes. Only 173 people (14.5%) had twelve-month weight data. In that group, people with diabetes lost 5.3% of their weight and people without lost 4.2% (p = 0.45). The diabetes group at twelve months was small, so this result cannot rule out a real difference.

Neither study assigned people to have diabetes, so neither can separate the effect of diabetes itself from medicines and everything else that differs between the groups.

Some earlier studies found the opposite. A 1987 comparison of people with diabetes and their overweight spouses reported that those with diabetes lost less weight. A 2000 study of an appetite-suppressant medicine found smaller falls in BMI among people with diabetes (7.98 against 4.77 kg/m², p < 0.01).

The defensible conclusion is narrower than “diabetes makes it harder”. Three questions are separate: how much you lose at first, how well you keep it off, and how you respond to weight-management medicines. This evidence does not show a consistent disadvantage across all three, and it does not rule one out. The one signal points to maintenance. No study here supports a fixed “diabetes penalty” in kilograms.

What Genuinely Changes The Picture: Your Prescription

This is where the difference is documented rather than assumed. RSSDI’s 2022 recommendations, from the Research Society for the Study of Diabetes in India, group glucose-lowering drugs by their usual effect on weight. The grouping is qualitative: it gives a direction for each class, not an average number of kilograms.

  • Usually cause weight gain: Insulin, sulfonylureas, meglitinides, and thiazolidinediones such as pioglitazone.
    • Insulin supports energy storage, and correcting high glucose also stops calories being lost in urine.
    • Insulin and the insulin-stimulating drugs (sulfonylureas and meglitinides) can cause hypoglycaemia (low blood sugar) when you eat less.
    • Thiazolidinedione weight gain can include fluid retention as well as fat.
  • Neutral to modest weight loss: Metformin, DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) and alpha-glucosidase inhibitors.
    • Lowering glucose does not by itself produce meaningful weight loss.
  • Usually cause weight loss: SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors) and GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists).
    • SGLT2 inhibitors increase the glucose lost in urine.
    • The effect of GLP-1 receptor agonists on appetite and intake varies substantially between agents.

Two points follow:

  • A drug’s weight effect is not the whole decision: “Weight-neutral” does not mean ineffective, and a drug linked to weight loss is not automatically right for you. Kidney protection, heart disease, hypoglycaemia risk, side effects, cost and access all matter.
  • A rising scale is not always new fat: When treatment is intensified, correcting very high blood sugar stops the calories that were being lost in urine, so weight can rise. That is different from diabetes preventing fat loss.

Whether any of this means your own regimen should change is a question for the doctor who prescribed it. Nothing here is a reason to alter or stop a medicine.

What Weight Loss Achieved In The Remission Trials

Two structured programmes give the clearest picture of what large weight loss does to established diabetes. Both began with supervised, very-low-calorie total diet replacement (formula meal replacements), followed by gradual food reintroduction and long-term support. In DiRECT, diabetes and blood pressure medicines were also withdrawn at the start under supervision.

  • DiRECT, UK, 2018 (Lean and colleagues): 306 primary-care adults aged 20 to 65, diagnosed within the past six years, with a BMI of 27 to 45 and none on insulin. 298 were analysed, 149 in each group. At one year, average loss was 10.0 kg against 1.0 kg with usual care (an adjusted difference of 8.8 kg), and remission occurred in 46% against 4%. At two years, remission was 36% against 3%.
  • DIADEM-I, Qatar, 2020 (Taheri and colleagues): Adults aged 18 to 50 from the Middle East and North Africa region, with diabetes for three years or less and a BMI of at least 27. 147 of the 158 people randomised were analysed. Average loss was 11.98 kg against 3.98 kg, and remission was reported in 61% against 12%.

Remission tracked how much weight people actually lost. Pooling everyone in DiRECT by their weight change at one year:

  • Gained weight: 0 of 76 were in remission.
  • Lost 0 to 5 kg: 6 of 89 (7%).
  • Lost 5 to 10 kg: 19 of 56 (34%).
  • Lost 10 to 15 kg: 16 of 28 (57%).
  • Lost 15 kg or more: 31 of 36 (86%).

There was no threshold at which everyone went into remission. Some people did with smaller losses, and some did not despite larger ones.

Both trials also chose their participants carefully. DiRECT excluded people on insulin and enrolled recent diagnoses, and DIADEM-I enrolled younger adults with short-duration diabetes. Their percentages do not transfer unchanged to older adults, long-standing diabetes or people on insulin. Neither trial was run in India, so their remission rates may not apply directly to Indian adults. RSSDI’s recommendations, above, are the Indian professional guidance on managing the condition.

Durability changes the picture again. In the DiRECT five-year extension, 95 intervention participants agreed to continued low-intensity support, and 85 had five-year data. Their average loss was 6.1 kg, and 11 of them (13%) were in remission. Among the original control group, 5 of the 93 with remission data (5%) were in remission.

This was not a fresh randomised comparison, and the group sizes change at each point. So “46% at one year” and “13% at five years” do not describe one group followed throughout.

Remission Has A Definition, And It Is Not A Cure

The word is used loosely because the definitions differ. The 2021 international consensus report, agreed by representatives of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), Diabetes UK and the Endocrine Society, sets these tests:

  • HbA1c below 6.5%: HbA1c is the blood test that reflects average blood sugar over roughly three months. Remission needs a result below 6.5% at least three months after stopping glucose-lowering medicine.
  • Alternative where HbA1c is unreliable: A fasting plasma glucose below 126 mg/dL.
  • After a lifestyle intervention: At least six months must have passed since the intervention began before remission is confirmed.

DiRECT used a slightly different test: HbA1c below 6.5% after at least two months off all diabetes medicines.

These medicine-free intervals are research and diagnostic definitions. They are not an instruction to stop treatment. Whether a medicine continues is a prescribing decision, and some medicines are there to protect your heart or kidneys rather than to lower glucose.

Remission is also not a cure. The consensus asks for HbA1c checks at least once a year, plus continued eye, kidney and foot checks, because insulin resistance and reduced insulin production may not return to normal and the condition can come back. Knowing the normal blood sugar ranges in India helps you follow those results over time.

Five Things That Change How Weight Loss Should Be Attempted

These five points change how you should go about weight loss when you have diabetes:

  • Hypoglycaemia risk belongs to the whole regimen, not one drug: When you eat less, insulin, sulfonylureas and meglitinides need particular attention, because their glucose-lowering effect can stop matching your food and activity. A drug with little risk of its own does not make a combination low-risk if insulin or an insulin-stimulating drug is also in the mix. Kidney problems and past low blood sugar episodes matter too.
  • Monitoring is part of the plan: RSSDI and ADA guidance say to discuss glucose monitoring whenever food intake or activity is changing, with your prescribing team deciding the method and timing. HbA1c shows the average. Day-to-day checks show the swings that matter while treatment is changing, and continuous glucose monitoring can reveal patterns that single readings miss when someone interprets them.
  • Existing retinopathy changes the pace: Rapid improvement in blood sugar can temporarily worsen diabetic eye disease (retinopathy), especially after a long period of poor control and when retinopathy is already more than minimal. The consensus report advises particular caution and repeat eye checks in that situation. That is an argument for your diabetes prescriber and eye-care team working together, not for leaving blood sugar uncontrolled.
  • Kidney disease changes which diet is safe: A generic high-protein plan is not automatically right alongside chronic kidney disease (CKD). ADA’s 2025 Standards of Care recommend 0.8 g of protein per kg of body weight per day for CKD stage G3 or higher without dialysis, and say 1.0 to 1.2 g/kg/day should be considered on dialysis. KDOQI (Kidney Disease Outcomes Quality Initiative) guidance, summarised in this review, suggests a lower 0.6 to 0.8 g/kg/day for diabetes with non-dialysis CKD. These are guideline figures, not a personal prescription: your stage, nutritional status and the right body-weight basis need assessment by your treating team. That is a different calculation from the general protein target per kg used when kidney function is normal.
  • Neuropathy changes the foot checks: ADA’s 2025 foot-care guidance asks for assessment of sensation, skin, deformity and circulation, and people with sensory loss or past ulcers need closer foot checks. Settle that before adding walking. Walking has its own measured effects on weight and blood sugar, but your feet need to be able to take it.

Where To Start

Start with a review before you begin a calorie deficit, not after. Bring:

  • Your full medicine list.
  • Your most recent HbA1c.
  • Any record of retinopathy, kidney function or foot problems.

Then ask:

  • Which of my medicines are in the weight-gain group?
  • What is the hypoglycaemia risk of my combination?
  • What monitoring should change as I eat less?
  • Does anything about my eyes, kidneys or feet change the plan?

A clinician-led metabolic review with Voy is built around exactly these questions, and it is where eligibility for any treatment is assessed rather than assumed. Talk to Voy about a clinician-led metabolic review to take the first step.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.

Related articles

4.7 / 5 (28,937+ reviews)

Still confused?

App Store
Download on theApp Store
Google Play
Get it onGoogle Play